The groundbreaking rise of Sildenafil presented a massive opportunity for shareholders , but its exclusivity has ended, creating a complex landscape. Alternative versions have flooded the space , cutting into profits and putting pressure on profit margins . While established pharmaceutical companies continue a stake in this field , the future looks